A Phase I Study of CREPT-618 in Locally Advanced HCC

This study is testing a new treatment called CREPT-618 — an experimental therapy designed to target liver cancer cells — in patients with locally advanced or metastatic hepatocellular carcinoma (HCC, the most common type of primary liver cancer) who have already tried standard treatments without success. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of advanced hepatocellular carcinoma - You have previously tried standard treatments and they did not work - You have inactive (not actively replicating) hepatitis B infection - Your liver cancer tissue tests positive for specific proteins the therapy targets (CREPT and ASGPR) - Your overall health and organ function are adequate for treatment **You may NOT be eligible if...** - You have active, replicating hepatitis B virus - You have not failed any prior standard treatment - Your overall health is too poor (ECOG score above 2) - Your liver, kidney, or blood counts are too low to tolerate treatment Talk to your doctor to see if this trial is right for you.